[
  {
    "sentence": "The worst fatality rates were observed in ALL, AML and MDS patients who were over 65 years old and female, ALL, AML and MDS patients over 65 years old with no comorbidities and CML and MPN patients who were over 65 years old and male (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The worst fatality rates were observed in ALL, AML and MDS patients who were over 65 years old and female, ALL, AML and MDS patients over 65 years old with no comorbidities and CML and MPN patients who were over 65 years old and male (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The impact of anti‐cancer treatments\nNo significant associations were observed between all‐cause mortality and treatment with cytotoxic chemotherapy in the four weeks prior to COVID‐19 diagnosis (Fig 2; OR 1·12, 95% CI 0·85–1·6).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "We also did not observe a significant association between with anti‐CD52 or anti‐CD19/anti‐CD20 treatment within two years prior to COVID‐19 diagnosis [Fig 2, anti‐CD52: OR 1·17 (95% CI 0·54–2·52); anti‐CD19/CD20: OR 0·91 (95% CI 0·61–1·36)].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Whilst based on small numbers there was also no evidence of an adverse impact of anti‐CD19/anti‐CD20 within four weeks of COVID‐19 infection (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Treatment with targeted agents in the four weeks prior to COVID‐19 diagnosis was significantly associated with a higher risk of all‐cause mortality [OR = 1·46 (95% CI 1·02–2·09), P = 0·037; Fig 2], but this association did not remain after adjusting for line of treatment [OR = 1·35 (95% CI 0·9–2·05), P = 0·15; Fig 3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "No results were generated to test the impact of radiotherapy and stem cell transplant because so few patients received these treatments (n = 9 and n = 8, respectively).Fig 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "No significant associations were observed between all‐cause mortality and treatment with cytotoxic chemotherapy in the four weeks prior to COVID‐19 diagnosis (Fig 2; OR 1·12, 95% CI 0·85–1·6).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "We also did not observe a significant association between with anti‐CD52 or anti‐CD19/anti‐CD20 treatment within two years prior to COVID‐19 diagnosis [Fig 2, anti‐CD52: OR 1·17 (95% CI 0·54–2·52); anti‐CD19/CD20: OR 0·91 (95% CI 0·61–1·36)].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Whilst based on small numbers there was also no evidence of an adverse impact of anti‐CD19/anti‐CD20 within four weeks of COVID‐19 infection (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Treatment with targeted agents in the four weeks prior to COVID‐19 diagnosis was significantly associated with a higher risk of all‐cause mortality [OR = 1·46 (95% CI 1·02–2·09), P = 0·037; Fig 2], but this association did not remain after adjusting for line of treatment [OR = 1·35 (95% CI 0·9–2·05), P = 0·15; Fig 3].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  }
]